British Journal of Cancer - Table of Contents alert Volume 105 Issue 8

TABLE OF CONTENTS Volume 105, Issue 8 (1105-1252) Published online 11 October 2011 In this issue Editorial Minireview Clinical Studies Translational Therapeutics Molecular Diagnostics Genetics and Genomics Corrigendum Also new today Advance online publication Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement British Journal of Cancer presents: Web Focus on RAS Mutations in RAS are emerging as critical in terms of responsiveness to antiEGFR therapies in bowel cancer and biology of lung cancer. This series describes many of the key studies relating to resistance to cetuximab in clinical practice, prognostic roles and roles in chemosensitisation, the effects of p53 on cetuximab and the interactions of RAS mutations with standard chemotherapy regimens.   Editorial Top Aspirin therapy for cancer: it is never too late J A Z Jankowski and P J Limburg Br J Cancer 2011 105: 1105-1106; 10.1038/bjc.2011.373 Full Text Minireview Top Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? R E Langley, S Burdett, J F Tierney, F Cafferty, M K B Parmar and G Venning Br J Cancer 2011 105: 1107-1113; advance online publication, August 16, 2011; 10.1038/bjc.2011.289 Abstract | Full Text The role of PARP in DNA repair and its therapeutic exploitation M Javle and N J Curtin Br J Cancer 2011 105: 1114-1122; 10.1038/bjc.2011.382 Abstract | Full Text Clinical Studies Top A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study) H LeCaer, F Barlesi, R Corre, H Jullian, S Bota, L Falchero, A Vergnenegre, C Dujon, J Y Delhoume and C Chouaid the GFPC 0504 Team Br J Cancer 2011 105: 1123-1130; advance online publication, September 20, 2011; 10.1038/bjc.2011.331 Abstract | Full Text Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer A Horiike, K Kudo, E Miyauchi, F Ohyanagi, K Kasahara, T Horai and M Nishio Br J Cancer 2011 105: 1131-1136; advance online publication, September 13, 2011; 10.1038/bjc.2011.375 Abstract | Full Text Prognostic discrimination of subgrouping node-positive endometrioid uterine cancer: location vs nodal extent D S Kapp, T K Kiet and J K Chan Br J Cancer 2011 105: 1137-1143; advance online publication, September 13, 2011; 10.1038/bjc.2011.336 Abstract | Full Text Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer C K Lee, R J Simes, C Brown, S Lord, U Wagner, M Plante, I Vergote, C Pisano, G Parma, A Burges, H Bourgeois, T Högberg, J Bentley, L Angleitner-Boubenizek, A Ferrero, B Richter, H Hirte, V Gebski, J Pfisterer, E Pujade-Lauraine and M Friedlander Br J Cancer 2011 105: 1144-1150; advance online publication, September 13, 2011; 10.1038/bjc.2011.364 Abstract | Full Text Estimated enterolignans, lignan-rich foods, and fibre in relation to survival after postmenopausal breast cancer K Buck, A K Zaineddin, A Vrieling, J Heinz, J Linseisen, D Flesch-Janys and J Chang-Claude Br J Cancer 2011 105: 1151-1157; advance online publication, September 13, 2011; 10.1038/bjc.2011.374 Abstract | Full Text Benefit finding and post-traumatic growth in long-term colorectal cancer survivors: prevalence, determinants, and associations with quality of life L Jansen, M Hoffmeister, J Chang-Claude, H Brenner and V Arndt Br J Cancer 2011 105: 1158-1165; advance online publication, August 30, 2011; 10.1038/bjc.2011.335 Abstract | Full Text The quality of web-based oncology guidelines and protocols: how do international sites stack up? J M Langton, A K Drew, L Mellish, J Olivier, R L Ward and S-A Pearson Br J Cancer 2011 105: 1166-1172; advance online publication, September 20, 2011; 10.1038/bjc.2011.378 Abstract | Full Text Translational Therapeutics Top Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours C M Korse, M Muller and B G Taal Br J Cancer 2011 105: 1173-1175; 10.1038/bjc.2011.380 Abstract | Full Text Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab P Todeschini, E Cocco, S Bellone, J Varughese, K Lin, L Carrara, F Guzzo, N Buza, P Hui, D-A Silasi, E Ratner, M Azodi, P E Schwartz, T J Rutherford, S Pecorelli and A D Santin Br J Cancer 2011 105: 1176-1182; advance online publication, September 13, 2011; 10.1038/bjc.2011.369 Abstract | Full Text Molecular Diagnostics Top HPV in exhaled breath condensate of lung cancer patients G E Carpagnano, A Koutelou, M I Natalicchio, D Martinelli, C Ruggieri, A Di Taranto, R Antonetti, F Carpagnano and M P Foschino-Barbaro Br J Cancer 2011 105: 1183-1190; advance online publication, September 27, 2011; 10.1038/bjc.2011.354 Abstract | Full Text Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma K Hotta, M Sho, K Fujimoto, K Shimada, I Yamato, S Anai, N Konishi, Y Hirao, K Nonomura and Y Nakajima Br J Cancer 2011 105: 1191-1196; advance online publication, September 20, 2011; 10.1038/bjc.2011.368 Abstract | Full Text Accurate staging of axillary lymph nodes from breast cancer patients using a novel molecular method T Osako, T Iwase, K Kimura, K Yamashita, R Horii and F Akiyama Br J Cancer 2011 105: 1197-1202; advance online publication, August 30, 2011; 10.1038/bjc.2011.350 Abstract | Full Text Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers R Shao, Q J Cao, R B Arenas, C Bigelow, B Bentley and W Yan Br J Cancer 2011 105: 1203-1209; advance online publication, September 20, 2011; 10.1038/bjc.2011.347 Abstract | Full Text Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer H Kaneda, T Arao, K Matsumoto, M A De Velasco, D Tamura, K Aomatsu, K Kudo, K Sakai, T Nagai, Y Fujita, K Tanaka, K Yanagihara, Y Yamada, I Okamoto, K Nakagawa and K Nishio Br J Cancer 2011 105: 1210-1217; advance online publication, September 6, 2011; 10.1038/bjc.2011.348 Abstract | Full Text Comparison of nuclear texture analysis and image cytometric DNA analysis for the assessment of dysplasia in Barrett's oesophagus J M Dunn, T Hveem, M Pretorius, D Oukrif, B Nielsen, F Albregtsen, L B Lovat, M R Novelli and H E Danielsen Br J Cancer 2011 105: 1218-1223; advance online publication, September 20, 2011; 10.1038/bjc.2011.353 Abstract | Full Text GSTPi-positive tumour microenvironment-associated fibroblasts are significantly associated with GSTPi-negative cancer cells in paired cases of primary invasive breast cancer and axillary lymph node metastases B Chaiwun, N Sukhamwang, H Trakultivakorn, B Saha, L Young, D Tsao-Wei, W Y Naritoku, S Groshen, C R Taylor and S A Imam Br J Cancer 2011 105: 1224-1229; advance online publication, September 6, 2011; 10.1038/bjc.2011.352 Abstract | Full Text Genetics and Genomics Top BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients Z Kote-Jarai, D Leongamornlert, E Saunders, M Tymrakiewicz, E Castro, N Mahmud, M Guy, S Edwards, L O'Brien, E Sawyer, A Hall, R Wilkinson, T Dadaev, C Goh, D Easton, The UKGPCS Collaborators, D Goldgar and R Eeles Br J Cancer 2011 105: 1230-1234; advance online publication, September 27, 2011; 10.1038/bjc.2011.383 Abstract | Full Text Src homology domain-containing phosphatase 2 suppresses cellular senescence in glioblastoma L-M Sturla, P O Zinn, K Ng, M Nitta, D Kozono, C C Chen and E M Kasper Br J Cancer 2011 105: 1235-1243; advance online publication, September 20, 2011; 10.1038/bjc.2011.345 Abstract | Full Text Is there a genetic cause for cancer cachexia? – a clinical validation study in 1797 patients T S Solheim, P M Fayers, T Fladvad, B Tan, F Skorpen, K Fearon, V E Baracos, P Klepstad, F Strasser and S Kaasa on behalf of the European Palliative Care Research Collaborative (EPCRC) and the European Pharmacogenetic Study (EPOS) Br J Cancer 2011 105: 1244-1251; advance online publication, September 20, 2011; 10.1038/bjc.2011.323 Abstract | Full Text Corrigendum Top Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer O A Khan, A D Blann, M J Payne, M R Middleton, A S Protheroe, D C Talbot, M Taylor, O Kirichek, C Han, M Patil and A L Harris Br J Cancer 2011 105: 1252; 10.1038/bjc.2011.411 Full Text Advertisement British Journal of Cancer presents: Guidelines for the Welfare of Animals in Cancer Research, 2010 Updated, enhanced, and providing practical advice on animal welfare specifically for today's cancer researchers, these guidelines define and encourage sharing of best practice in laboratory work. Already endorsed by leading scientists worldwide, they should also be read by those making decisions about licensing, funding and publication. Read the guidelines here.   Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2011 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.